FLT3 and acute myeloid leukemia: Although a significant higher number of patients in CLAG‐M group achieved CR and had a better prognosis after one‐cycle chemotherapy than conventional chemotherapy, we showed that CLAG‐M regimen did not yield improvements for every R/R‐AML patients, and the response rate and prognosis remains disappointing in FLT3‐ITD patients no matter in the CLAG‐M group or MEC/IEC group.